Cargando…

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

Immunomodulatory drugs and monoclonal antibody-based immunotherapies have significantly improved the prognosis of the patients with multiple myeloma (MM) in the recent years. These new classes of reagents target malignant plasma cells (PCs) and further modulate the immune microenvironment, which pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tai, Yu-Tzu, Cho, Shih-Feng, Anderson, Kenneth C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095980/ https://www.ncbi.nlm.nih.gov/pubmed/30147691 http://dx.doi.org/10.3389/fimmu.2018.01822

Ejemplares similares

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
por: Cho, Shih-Feng, et al.
Publicado: (2018)

Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma
por: Mansour, Anna, et al.
Publicado: (2017)

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
por: Tai, Yu-Tzu, et al.
Publicado: (2018)

Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2021)

Bispecific antibodies in multiple myeloma treatment: A journey in progress
por: Cho, Shih-Feng, et al.
Publicado: (2022)

Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma
por: Lv, Junqiang, et al.
Publicado: (2022)

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2017)

Regulatory role of the programmed cell death 1 signaling pathway in sepsis induced immunosuppression
por: Zhong, Shubai, et al.
Publicado: (2023)

Antibody-Based Therapies in Multiple Myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2011)

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2020)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
por: Nadeem, Omar, et al.
Publicado: (2020)

Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
por: Jiang, Yao, et al.
Publicado: (2023)

The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental Settings
por: Greisen, Stinne R., et al.
Publicado: (2022)

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma
por: Bae, Jooeun, et al.
Publicado: (2021)

Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
por: Fujiwara, Mai, et al.
Publicado: (2017)

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells
por: Zhu, Chen, et al.
Publicado: (2020)

Editorial: The Role of Microorganisms in Multiple Myeloma
por: Linares, Maria, et al.
Publicado: (2022)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
por: Shen, Xiangfeng, et al.
Publicado: (2019)

Programmed Cell Death-1 and Its Ligands as Targets for Therapy of Multiple Myeloma Patients
por: Karczmarczyk, Agnieszka, et al.
Publicado: (2022)

Causal relationships between gut microbiota and programmed cell death protein 1/programmed cell death-ligand 1: A bidirectional Mendelian randomization study
por: Huang, Yu-Feng, et al.
Publicado: (2023)

Protective Role of Programmed Death 1 Ligand 1 (PD-L1)in Nonobese Diabetic Mice : The Paradox in Transgenic Models
por: Wang, Chia-Jen, et al.
Publicado: (2008)

The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1(+) regulator B cells mediates immunosuppression in triple-negative breast cancer
por: Li, Xuejiao, et al.
Publicado: (2022)

Interplay between programmed death-ligand 1 and non-coding RNAs
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2022)

Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews
por: Ou, Shun-Long, et al.
Publicado: (2022)

Prognostic Significance of the Dynamic Change of Programmed Death-ligand 1 Expression in Patients with Multiple Myeloma
por: Guan, Jian, et al.
Publicado: (2019)

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

IL-1β, But Not Programed Death-1 and Programed Death Ligand Pathway, Is Critical for the Human Th17 Response to Mycobacterium tuberculosis
por: Stephen-Victor, Emmanuel, et al.
Publicado: (2016)

Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
por: Wang, Yiming, et al.
Publicado: (2018)

Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody
por: Kalim, Muhammad, et al.
Publicado: (2022)

Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche
por: Chillemi, Antonella, et al.
Publicado: (2017)

Targeting CD38 alleviates tumor-induced immunosuppression
por: Tai, Yu-Tzu, et al.
Publicado: (2017)

Transcriptome profiling of osteoclast subsets associated with arthritis: A pathogenic role of CCR2(hi) osteoclast progenitors
por: Filipović, Maša, et al.
Publicado: (2022)

Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis
por: Xian, Feng, et al.
Publicado: (2023)

Monomeric C-Reactive Protein Binds and Neutralizes Receptor Activator of NF-κB Ligand-Induced Osteoclast Differentiation
por: Jia, Zhe-Kun, et al.
Publicado: (2018)

Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients
por: Zhaoyun, Liu, et al.
Publicado: (2021)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

The Role of Myeloid Cells in GBM Immunosuppression
por: Lin, Ya-Jui, et al.
Publicado: (2022)

Macrophage-Osteoclast Associations: Origin, Polarization, and Subgroups
por: Sun, Yang, et al.
Publicado: (2021)

Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells
por: Liang, Zhaoduan, et al.
Publicado: (2023)

Corrigendum: Monomeric C-Reactive Protein Binds and Neutralizes Receptor Activator of NF-κB Ligand-Induced Osteoclast Differentiation
por: Jia, Zhe-Kun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nn40p6knja41v1i2rol79n807c